Search | Clinical Trials Finder

Conditions: Menopause Related Conditions
Interventions: Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Hofseth Biocare ASA; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (BMS-188667), Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more

Conditions: Type 2 Diabetes Mellitus
Interventions: efpeglenatide (SAR439977), placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 24 more

Conditions: Neoplasm of Pancreas, IPMN, Pancreatic
Interventions: Vitamin E Delta Tocotrienol, Placebo; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Alzheimer Disease
Interventions: bapineuzumab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more

Conditions: Crohn's Disease
Interventions: placebo for risankizumab IV, risankizumab SC, risankizumab IV; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 114
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Certolizumab pegol; Other · Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Venous Thromboembolism (VTE)
Interventions: Betrixaban, Enoxaparin; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 7,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 75
States / cities: Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Alzheimer Disease and Related Dementias, Cognition, Mobility Disability
Interventions: Personalized Transcranial Direct Current Stimulation (tDCS), Active-Sham; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years to 90 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Cardiomyopathy, Hypertrophic Obstructive
Interventions: CT-G20, Placebo; Drug
Lead sponsor: Celltrion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Otolaryngeal Cancer
Interventions: Ketamine, Placebo, Electroencephalogram (EEG); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 22
States / cities: Encinitas, California • Lancaster, California • Los Angeles, California + 19 more

Conditions: Damage Muscle, Body Weight Changes, Performance Enhancing Product Use
Interventions: Pre-workout plus and Protein recovery plus, Placebo, 6-week resistance training program; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 25 Years to 50 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Oily Skin, Seborrhea
Interventions: MTC896 Gel; Drug
Lead sponsor: Mimetica Pty Limited; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Kidney Stones
Interventions: LLX-424; Drug
Lead sponsor: Lilac Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Springfield, Missouri • San Antonio, Texas

Conditions: Infections, Bacterial Infections
Interventions: TD-1607, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cyclosporine ophthalmic emulsion, placebo; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more

Conditions: Glut1 Deficiency, GLUT1DS1
Interventions: L-fucose, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

ProGo Menopause Wellbeing Study

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Abatacept With Methotrexate- Phase IIB

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Chronic Study on Body Composition, Training, Performance, and Recovery

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones

TD-1607 MAD Study in Healthy Subjects

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome